Lilly Adds Two More Humalog Authorized Generics As Insurance Deductibles Reset
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.
You may also be interested in...
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Rebates would be prohibited and insurance coverage required without restrictions for insulin products with steep price roll-backs under bill from Reps. Diana DeGette, D-CO, and Tom Reed, R-NY.
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.